All News

Article

Antiphospholipid Antibodies With Incident Cardiovascular Events

Jack Cush, MD Apr 06, 2023

Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk? A cohort study has shown that aPL Abs are found in a substantial proportion of adults with ASCVD events and finding both positive aCL IgA and aβ2GPI IgA Abs independently predicted futur

Article

Our old friend, hydroxychloroquine

Eric Dein, MD Mar 22, 2023

After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.

Join us April 18 for: Private Practice & Academia In this session, our panelists will address the big questions of: "How do I choose between private practice and academia?" and "How do I advance in my career?". https://t.co/BrWG57mRRG https://t.co/A0pzEvJ3cu

https://bit.ly/3UzGT0y

Dr. Megan Clowse discusses the differences in pregnancy planning for men and women with rheumatic disease, with particular focus on medication use. Watch now. https://t.co/Ine8CdbZR4 https://t.co/7UnanlnQcC

https://bit.ly/3Kod7r1

Antiphospholipid Antibodies With Incident Cardiovascular Events Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk? https://t.co/XQk17P6D2f https://t.co/y5exrsicW8

https://bit.ly/3nOx6r9

RheumThoughts: Changing the Conversation with Patients: Lupus Join the discussion! RheumThoughts are opinion pieces from healthcare professionals. https://t.co/NcJcCZVlbE @drbags71 https://t.co/VfAqUkqLak

https://bit.ly/41n0OlK

RheumThoughts: Changing the Conversation with Patients: Lupus https://t.co/rFM2211Toq https://t.co/I9yWGMCH9B

https://bit.ly/3mgA73b

The Origin Story: Women in Rheumatology--The XX Factor When asked to run a campaign to highlight the achievements and challenges of women in rheumatology, I was ecstatic because we have has so many heroines who have contributed to our field. https://t.co/ucQIPjQ8Tu https://t.co/g81EtAwYYL

https://bit.ly/3Ku6G6T

Drs. Tate and Dao will be leading discussions on Women in Rheumatology, the XX Factor. Sign up to attend our Tuesday Night Rheumatology series. @uptoTate @KDAO2011 https://t.co/ciEAY1SJdg https://t.co/dlCfXItAxN

https://bit.ly/3M9jyRg

Tomorrow! Join us for Tuesday Night Rheumatology. Our panelists will discuss the challenges they have faced trying to manage a career and family life, as well as provide advice and strategies for managing competing priorities and obligations. https://t.co/OlP0pupkMV https://t.co/pZQMASafcG

https://bit.ly/3M450lN

Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SLEek) Phase 2 trial met the primary endpoint SRI-4 response and pred dose<=10 mg qd. No new safety signals - Phase III trial planned https://t.co/6CwS2AVamH https://t.co/b4wQ6IoiOz

https://bit.ly/3nG1fJ5

Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/RCtQnA9vc9 https://t.co/G5cXukkpUB

https://bit.ly/3nnYfBh

LRA announces the 2023 recipients of the Lupus Innovation Award during #NationalKidneyMonth as three of this year’s seven award recipients are studying issues that come with this too-common complication. 🧵1of2 https://t.co/VZL9qJu9kF

Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW

https://bit.ly/40sbhfe

The AURORA study with voclosporin has changed the way that Dr. Kalunian practices. He now uses lower doses of steroid, 40mg in induction with a faster taper in lupus nephritis. #RNL2023 @RheumNow https://t.co/8ss14Z5WXl

Reassuring data by Dr. Laurent Arnaud on HCQ - arrhythmia risk from HCQ similar to general population @RheumNow #RNL2023 https://t.co/vMDg2SlbJQ

A Pilot Trial of Anifrolumab in Discoid Lupus A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE). https://t.co/MwruMhmvPq https://t.co/WnCvCZtq6z

https://bit.ly/3JovThn

BEAT LUPUS trial results showed that belimumab after RTX reduced dsDNA levels/flaring. Questions remain if this can be a successful combination in lupus nephritis. Dr. Kalunian #RNL2023 @RheumNow https://t.co/XeuybrWigf

@RheumNow's review of new drug approvals during 2022 at #RNL2023 https://t.co/IgndlG6lOI

How does HCQ work @Lupusreference in #RNL2023 HCQ works by inhibition of Toll-like receptor (TLR) with affects on IFN HCQ works as base to increase lysosomal pH and affect cellular function @RheumNow https://t.co/RTEUF0cS0u

Topics

All News

Antiphospholipid Antibodies With Incident Cardiovascular Events

Our old friend, hydroxychloroquine

Do you get our email newsletter?